Spots Global Cancer Trial Database for Combining Epigenetic And Immune Therapy to Beat Cancer.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Combining Epigenetic And Immune Therapy to Beat Cancer.

Official Title: Combining Epigenetic And Immune Therapy to Beat Cancer. CAIRE Study

Study ID: NCT04705818

Conditions

Advanced Solid Tumor

Advanced Colorectal Carcinoma

Advanced Soft-tissue Sarcoma

Advanced Pancreatic Adenocarcinoma

Adult Solid Tumor

Interventions

Durvalumab

Tazemetostat

Study Description

Brief Summary: Umbrella study structure to independently and simultaneously assess the effects of the association of durvalumab and tazemetostat in multiple solid tumors.

Detailed Description: 4 independant, multicenter, prospective, signle-arm phase II trials, based on 2-stage Simon's optimal design, will be conducted in parallel to assess the efficacy of durvalumab when prescribed with tazemetostat, separately, in distinct cohorts of solid tumors: * cohort A: patients with pancreatic cancer * cohort B: patients with colorectal cancer not MSI-H or MMR-deficient * cohort C: patients with metastatic solid tumors with positive interferon gamma signature and/or tertiary lymphoid structure positive * cohort D: patients with soft-tissue sarcoma